Results 211 to 220 of about 445,727 (296)

Bifunctional Artificial Enzymes‐Loaded Microgels With LOX‐ and CAT‐Like Activities for Metabolic Reprogramming and Scarless Wound Repair

open access: yesAdvanced Science, EarlyView.
A bifunctional lactate oxidase‐like and catalase‐like artificial enzyme (Metazyme) is integrated into a rod‐shaped microgel (MetaRgel) to enable cascade lactate oxidation and oxygen regeneration. By reprogramming the wound metabolic microenvironment, MetaRgel alleviates excessive lactate accumulation, oxidative stress, hypoxia, and inflammation ...
Yongyuan Kang   +9 more
wiley   +1 more source

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

open access: yesAdvanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li   +10 more
wiley   +1 more source

NSUN5 Attenuates Renal Injury and Ferroptosis in Hyperuricaemic Nephropathy Through YBX2‐Dependent Stabilisation of SCD1 m5C Methylation

open access: yesAdvanced Science, EarlyView.
NSUN5 is downregulated in hyperuricaemic nephropathy. Overexpression of NSUN5 enhances the stability of SCD1 mRNA through the m5C reader YBX2, ultimately inhibiting ferroptosis in renal tubular epithelial cells. Additionally, this axis suppresses the NF‐κB signaling pathway to alleviate inflammation and upregulates ABCG2 to promote uric acid excretion,
Xiu‐xiu Song   +12 more
wiley   +1 more source

The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy.

open access: yesBlood
Hawerkamp HC   +19 more
europepmc   +1 more source

First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria

open access: yesAdvanced Science, EarlyView.
We report the first PROTACs designed to degrade progerin, introducing a novel therapeutic approach for progeria. The best compound, UCM‐18142, significantly reduces progerin levels and improves key disease phenotypes in patient‐derived cells and in the LmnaG609G/G609G mouse model, paving the way for new treatment strategies targeting the root cause of ...
Jon Macicior‐Michelena   +5 more
wiley   +1 more source

Interleukin-33: A Double-Edged Sword in Sepsis. [PDF]

open access: yesTransl Perioper Pain Med
Liu S, Yue Y, Wu Q, Zhang LM.
europepmc   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

open access: yesAdvanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun   +15 more
wiley   +1 more source

Interleukin 33 Promotes Liver Sinusoidal Endothelial Cell Dysfunction and Hepatic Fibrosis in Diabetic Mice. [PDF]

open access: yesDiabetes Metab J
Chen H   +13 more
europepmc   +1 more source

A Mitochondria‐Specific Nanomedicine for Synergistic Chemo‐Photothermal Therapy and Immunogenic Activation Against Breast Cancer

open access: yesAdvanced Science, EarlyView.
Peptide dendrimer–based nanoplatform with mitochondria‐targeting capability was developed for synergistic chemo‐photothermal therapy. The system promotes efficient transcytosis, induces mitochondrial dysfunction, triggers immunogenic cell death (ICD), and enhance antitumor immunity by promoting dendritic cell maturation and T‐cell activation, resulting
Min Li   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy